tiprankstipranks
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
US Market
Want to see SYRE full AI Analyst Report?

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

552 Followers
See the Price Targets and Ratings of:

SYRE Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Spyre
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SYRE Stock 12 Month Forecast

Average Price Target

$94.86
▲(29.92% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Spyre Therapeutics in the last 3 months. The average price target is $94.86 with a high forecast of $115.00 and a low forecast of $80.00. The average price target represents a 29.92% change from the last price of $73.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","116":"$116","38.75":"$38.8","64.5":"$64.5","90.25":"$90.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.85714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,38.75,64.5,90.25,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.42,72.92615384615385,76.43230769230769,79.93846153846154,83.44461538461539,86.95076923076923,90.45692307692308,93.96307692307693,97.46923076923076,100.97538461538461,104.48153846153846,107.9876923076923,111.49384615384615,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.42,71.3767032967033,73.3334065934066,75.29010989010989,77.24681318681318,79.20351648351648,81.16021978021978,83.11692307692307,85.07362637362637,87.03032967032966,88.98703296703296,90.94373626373626,92.90043956043955,{"y":94.85714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.42,70.23384615384616,71.04769230769232,71.86153846153846,72.67538461538462,73.48923076923077,74.30307692307693,75.11692307692307,75.93076923076923,76.74461538461539,77.55846153846154,78.37230769230769,79.18615384615384,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$115.00Average Price Target$94.86Lowest Price Target$80.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on SYRE
LifeSci Capital
LifeSci Capital
$105$103
Buy
41.08%
Upside
Reiterated
05/06/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Spyre Therapeutics (NASDAQ: SYRE) and Adaptive Biotechnologies (NASDAQ: ADPT)
BTIG
$98
Buy
34.23%
Upside
Reiterated
05/06/26
Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
Stifel Nicolaus Analyst forecast on SYRE
Stifel Nicolaus
Stifel Nicolaus
$92$107
Buy
46.56%
Upside
Assigned
05/06/26
Spyre Therapeutics price target raised to $107 from $92 at StifelSpyre Therapeutics price target raised to $107 from $92 at Stifel
Jefferies Analyst forecast on SYRE
Jefferies
Jefferies
$85$95
Buy
30.12%
Upside
Reiterated
05/06/26
Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
Citi
$64$97
Buy
32.86%
Upside
Assigned
05/06/26
Spyre Therapeutics price target raised to $97 from $64 at CitiSpyre Therapeutics price target raised to $97 from $64 at Citi
TD Cowen
Buy
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)
Wedbush
$80
Buy
9.57%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Evercore ISI Analyst forecast on SYRE
Evercore ISI
Evercore ISI
Buy
Reiterated
04/30/26
Analysts Conflicted on These Healthcare Names: Teladoc (NYSE: TDOC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Guggenheim Analyst forecast on SYRE
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$115
Buy
57.51%
Upside
Reiterated
04/29/26
Guggenheim Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
JonesTrading
$95
Buy
30.12%
Upside
Reiterated
04/29/26
Spyre Therapeutics: Buy Rating Reaffirmed as External Combo Data Support IBD Strategy; $95 Price Target Unchanged
Wells Fargo Analyst forecast on SYRE
Wells Fargo
Wells Fargo
$50$90
Buy
23.27%
Upside
Assigned
04/14/26
Spyre Therapeutics price target raised to $90 from $50 at Wells FargoSpyre Therapeutics price target raised to $90 from $50 at Wells Fargo
Deutsche Bank  Analyst forecast on SYRE
Deutsche Bank
Deutsche Bank
$55$88
Buy
20.53%
Upside
Reiterated
04/14/26
Spyre Therapeutics price target raised to $88 from $55 at Deutsche BankSpyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
Mizuho Securities Analyst forecast on SYRE
Mizuho Securities
Mizuho Securities
$53$84
Buy
15.05%
Upside
Reiterated
04/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alfresa Holdings (Other OTC: ARHCF), Spyre Therapeutics (NASDAQ: SYRE) and Eisai Co (Other OTC: ESALF)
Robert W. Baird Analyst forecast on SYRE
Robert W. Baird
Robert W. Baird
$65$90
Buy
23.27%
Upside
Reiterated
04/14/26
Spyre Therapeutics price target raised to $90 from $65 at BairdSpyre Therapeutics price target raised to $90 from $65 at Baird
Leerink Partners Analyst forecast on SYRE
Leerink Partners
Leerink Partners
$49$106
Buy
45.19%
Upside
Reiterated
04/13/26
Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on SYRE
LifeSci Capital
LifeSci Capital
$105$103
Buy
41.08%
Upside
Reiterated
05/06/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Spyre Therapeutics (NASDAQ: SYRE) and Adaptive Biotechnologies (NASDAQ: ADPT)
BTIG
$98
Buy
34.23%
Upside
Reiterated
05/06/26
Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
Stifel Nicolaus Analyst forecast on SYRE
Stifel Nicolaus
Stifel Nicolaus
$92$107
Buy
46.56%
Upside
Assigned
05/06/26
Spyre Therapeutics price target raised to $107 from $92 at StifelSpyre Therapeutics price target raised to $107 from $92 at Stifel
Jefferies Analyst forecast on SYRE
Jefferies
Jefferies
$85$95
Buy
30.12%
Upside
Reiterated
05/06/26
Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
Citi
$64$97
Buy
32.86%
Upside
Assigned
05/06/26
Spyre Therapeutics price target raised to $97 from $64 at CitiSpyre Therapeutics price target raised to $97 from $64 at Citi
TD Cowen
Buy
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)
Wedbush
$80
Buy
9.57%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Evercore ISI Analyst forecast on SYRE
Evercore ISI
Evercore ISI
Buy
Reiterated
04/30/26
Analysts Conflicted on These Healthcare Names: Teladoc (NYSE: TDOC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Guggenheim Analyst forecast on SYRE
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$115
Buy
57.51%
Upside
Reiterated
04/29/26
Guggenheim Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
JonesTrading
$95
Buy
30.12%
Upside
Reiterated
04/29/26
Spyre Therapeutics: Buy Rating Reaffirmed as External Combo Data Support IBD Strategy; $95 Price Target Unchanged
Wells Fargo Analyst forecast on SYRE
Wells Fargo
Wells Fargo
$50$90
Buy
23.27%
Upside
Assigned
04/14/26
Spyre Therapeutics price target raised to $90 from $50 at Wells FargoSpyre Therapeutics price target raised to $90 from $50 at Wells Fargo
Deutsche Bank  Analyst forecast on SYRE
Deutsche Bank
Deutsche Bank
$55$88
Buy
20.53%
Upside
Reiterated
04/14/26
Spyre Therapeutics price target raised to $88 from $55 at Deutsche BankSpyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
Mizuho Securities Analyst forecast on SYRE
Mizuho Securities
Mizuho Securities
$53$84
Buy
15.05%
Upside
Reiterated
04/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alfresa Holdings (Other OTC: ARHCF), Spyre Therapeutics (NASDAQ: SYRE) and Eisai Co (Other OTC: ESALF)
Robert W. Baird Analyst forecast on SYRE
Robert W. Baird
Robert W. Baird
$65$90
Buy
23.27%
Upside
Reiterated
04/14/26
Spyre Therapeutics price target raised to $90 from $65 at BairdSpyre Therapeutics price target raised to $90 from $65 at Baird
Leerink Partners Analyst forecast on SYRE
Leerink Partners
Leerink Partners
$49$106
Buy
45.19%
Upside
Reiterated
04/13/26
Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Spyre Therapeutics

3 Months
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+19.25%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +19.25% per trade.
1 Year
Alex Thompson CFAStifel Nicolaus
Success Rate
10/13 ratings generated profit
77%
Average Return
+95.60%
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +95.60% per trade.
2 Years
xxx
Success Rate
18/18 ratings generated profit
100%
Average Return
+174.72%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +174.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYRE Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
11
11
11
13
11
Buy
3
7
10
28
29
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
18
21
41
40
In the current month, SYRE has received 40 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SYRE average Analyst price target in the past 3 months is 94.86.
Each month's total comprises the sum of three months' worth of ratings.

SYRE Financial Forecast

SYRE Earnings Forecast

Next quarter’s earnings estimate for SYRE is -$0.72 with a range of -$0.90 to -$0.51. The previous quarter’s EPS was -$0.74. SYRE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.
Next quarter’s earnings estimate for SYRE is -$0.72 with a range of -$0.90 to -$0.51. The previous quarter’s EPS was -$0.74. SYRE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Sales Forecast

Next quarter’s sales forecast for SYRE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SYRE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.
Next quarter’s sales forecast for SYRE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SYRE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Stock Forecast FAQ

What is SYRE’s average 12-month price target, according to analysts?
Based on analyst ratings, Spyre Therapeutics’s 12-month average price target is 94.86.
    What is SYRE’s upside potential, based on the analysts’ average price target?
    Spyre Therapeutics has 29.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SYRE a Buy, Sell or Hold?
          Spyre Therapeutics has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Spyre Therapeutics’s price target?
            The average price target for Spyre Therapeutics is 94.86. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $115.00 ,the lowest forecast is $80.00. The average price target represents 29.92% Increase from the current price of $73.01.
              What do analysts say about Spyre Therapeutics?
              Spyre Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of SYRE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.